CXCL8 and non-small cell lung carcinoma: reported that increased level of IL-8 (3 months after immunotherapy) was correlated with prolonged OS (P=0.015) in 26 NSCLC patients treated with first or second line anti-PD-1 (nivolumab or pembrolizumab) (21).